Bioenvision Inc.

Bioenvision's primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra®, Modrenal®(for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing Suvus®, its anti-infective technology, which is currently in clinical development for refractory chronic hepatitis C infection. For more information on Bioenvision please visit our Web site at www.bioenvision.com.

Related Events
Date/Time		Description
Sep 12 2007		2007 Year-End Results Conference Call
Nov 9 2006		First Quarter 2007 Results Conference Call
May 15 2006		Third Quarter 2006 Results Conference Call

Market Assistant		PrecisionAlert
Earnings Data Annual Report Press Releases		Enter your email address to receive alerts about this company